pancreatic neoplasms

Summary

Summary: Tumors or cancer of the PANCREAS. Depending on the types of ISLET CELLS present in the tumors, various hormones can be secreted: GLUCAGON from PANCREATIC ALPHA CELLS; INSULIN from PANCREATIC BETA CELLS; and SOMATOSTATIN from the SOMATOSTATIN-SECRETING CELLS. Most are malignant except the insulin-producing tumors (INSULINOMA).

Top Publications

  1. pmc Core signaling pathways in human pancreatic cancers revealed by global genomic analyses
    Sian Jones
    Sol Goldman Pancreatic Cancer Research Center, Ludwig Center and Howard Hughes Medical Institute at the Johns Hopkins Kimmel Cancer Center, Baltimore, MD 21231, USA
    Science 321:1801-6. 2008
  2. ncbi FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer
    Thierry Conroy
    Nancy University and Department of Medical Oncology, Centre Alexis Vautrin, Nancy, France
    N Engl J Med 364:1817-25. 2011
  3. ncbi Distinct populations of cancer stem cells determine tumor growth and metastatic activity in human pancreatic cancer
    Patrick C Hermann
    Department of Surgery, Ludwig Maximilians University, 81377 Munich, Germany
    Cell Stem Cell 1:313-23. 2007
  4. ncbi Identification of pancreatic cancer stem cells
    Chenwei Li
    Department of Surgery, University of Michigan Medical Center, 1500 East Medical Center Drive, Ann Arbor, MI 48109, USA
    Cancer Res 67:1030-7. 2007
  5. pmc Distant metastasis occurs late during the genetic evolution of pancreatic cancer
    Shinichi Yachida
    Department of Pathology, The Sol Goldman Pancreatic Cancer Research Center, Johns Hopkins Medical Institutions, Baltimore, Maryland 21231, USA
    Nature 467:1114-7. 2010
  6. ncbi Pancreatic cancer
    Audrey Vincent
    Department of Pathology, Sol Goldman Pancreatic Cancer Research Center, Johns Hopkins Medical Institutions, Johns Hopkins University, Baltimore, MD 21231, USA
    Lancet 378:607-20. 2011
  7. pmc Everolimus for advanced pancreatic neuroendocrine tumors
    James C Yao
    University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    N Engl J Med 364:514-23. 2011
  8. pmc Inhibition of Hedgehog signaling enhances delivery of chemotherapy in a mouse model of pancreatic cancer
    Kenneth P Olive
    Cancer Research UK, Cambridge Research Institute, Li Ka Shing Centre, Robinson Way, Cambridge CB2 ORE, UK
    Science 324:1457-61. 2009
  9. ncbi Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group
    Malcolm J Moore
    Division of Medical Oncology, Princess Margaret Hospital, Toronto, Canada
    J Clin Oncol 25:1960-6. 2007
  10. ncbi Preinvasive and invasive ductal pancreatic cancer and its early detection in the mouse
    Sunil R Hingorani
    Department of Medicine, Abramson Family Cancer Research Institute, Abramson Center at the University of Pennsylvania, Philadelphia, PA 19104, USA
    Cancer Cell 4:437-50. 2003

Detail Information

Publications297 found, 100 shown here

  1. pmc Core signaling pathways in human pancreatic cancers revealed by global genomic analyses
    Sian Jones
    Sol Goldman Pancreatic Cancer Research Center, Ludwig Center and Howard Hughes Medical Institute at the Johns Hopkins Kimmel Cancer Center, Baltimore, MD 21231, USA
    Science 321:1801-6. 2008
    ..Dysregulation of these core pathways and processes through mutation can explain the major features of pancreatic tumorigenesis...
  2. ncbi FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer
    Thierry Conroy
    Nancy University and Department of Medical Oncology, Centre Alexis Vautrin, Nancy, France
    N Engl J Med 364:1817-25. 2011
    ....
  3. ncbi Distinct populations of cancer stem cells determine tumor growth and metastatic activity in human pancreatic cancer
    Patrick C Hermann
    Department of Surgery, Ludwig Maximilians University, 81377 Munich, Germany
    Cell Stem Cell 1:313-23. 2007
    ..Strategies aimed at modulating the SDF-1/CXCR4 axis may have important clinical applications to inhibit metastasis of cancer stem cells...
  4. ncbi Identification of pancreatic cancer stem cells
    Chenwei Li
    Department of Surgery, University of Michigan Medical Center, 1500 East Medical Center Drive, Ann Arbor, MI 48109, USA
    Cancer Res 67:1030-7. 2007
    ....
  5. pmc Distant metastasis occurs late during the genetic evolution of pancreatic cancer
    Shinichi Yachida
    Department of Pathology, The Sol Goldman Pancreatic Cancer Research Center, Johns Hopkins Medical Institutions, Baltimore, Maryland 21231, USA
    Nature 467:1114-7. 2010
    ..These data provide novel insights into the genetic features underlying pancreatic cancer progression and define a broad time window of opportunity for early detection to prevent deaths from metastatic disease...
  6. ncbi Pancreatic cancer
    Audrey Vincent
    Department of Pathology, Sol Goldman Pancreatic Cancer Research Center, Johns Hopkins Medical Institutions, Johns Hopkins University, Baltimore, MD 21231, USA
    Lancet 378:607-20. 2011
    ..In this Seminar we will discuss the most common and deadly form of pancreatic cancer, pancreatic ductal adenocarcinoma...
  7. pmc Everolimus for advanced pancreatic neuroendocrine tumors
    James C Yao
    University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    N Engl J Med 364:514-23. 2011
    ..We evaluated the agent in a prospective, randomized, phase 3 study...
  8. pmc Inhibition of Hedgehog signaling enhances delivery of chemotherapy in a mouse model of pancreatic cancer
    Kenneth P Olive
    Cancer Research UK, Cambridge Research Institute, Li Ka Shing Centre, Robinson Way, Cambridge CB2 ORE, UK
    Science 324:1457-61. 2009
    ..Thus, inefficient drug delivery may be an important contributor to chemoresistance in pancreatic cancer...
  9. ncbi Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group
    Malcolm J Moore
    Division of Medical Oncology, Princess Margaret Hospital, Toronto, Canada
    J Clin Oncol 25:1960-6. 2007
    ..We studied the effects of adding the HER1/EGFR-targeted agent erlotinib to gemcitabine in patients with unresectable, locally advanced, or metastatic pancreatic cancer...
  10. ncbi Preinvasive and invasive ductal pancreatic cancer and its early detection in the mouse
    Sunil R Hingorani
    Department of Medicine, Abramson Family Cancer Research Institute, Abramson Center at the University of Pennsylvania, Philadelphia, PA 19104, USA
    Cancer Cell 4:437-50. 2003
    ..Finally, mice with PanINs have an identifiable serum proteomic signature, suggesting a means of detecting the preinvasive state in patients...
  11. ncbi Sunitinib malate for the treatment of pancreatic neuroendocrine tumors
    Eric Raymond
    Service Inter Hospitalier de Cancérologie et Service de Gastroenteropancréatologie, Hopital Beaujon, Clichy, France
    N Engl J Med 364:501-13. 2011
    ..The multitargeted tyrosine kinase inhibitor sunitinib has shown activity against pancreatic neuroendocrine tumors in preclinical models and phase 1 and 2 trials...
  12. pmc EMT and dissemination precede pancreatic tumor formation
    Andrew D Rhim
    Gastroenterology Division, Department of Medicine, University of Pennsylvania School of Medicine, Philadelphia, PA 19104, USA
    Cell 148:349-61. 2012
    ..These results provide insight into the earliest events of cellular invasion in situ and suggest that inflammation enhances cancer progression in part by facilitating EMT and entry into the circulation...
  13. pmc The patterns and dynamics of genomic instability in metastatic pancreatic cancer
    Peter J Campbell
    Cancer Genome Project, Wellcome Trust Sanger Institute, Hinxton CB10 1SA, UK
    Nature 467:1109-13. 2010
    ..These data attest to the richness of genetic variation in cancer, brought about by the tandem forces of genomic instability and evolutionary selection...
  14. pmc Pancreatic cancer
    Donghui Li
    Department of Gastrointestinal Medical Oncology, University of Texas, M D Anderson Cancer Center, 1515 Holcombe Boulevard, Box 426, Houston, TX 77030, USA
    Lancet 363:1049-57. 2004
    ..However, new therapeutic strategies based on the molecular biology of pancreatic cancer seem to hold the greatest promise...
  15. pmc Pancreatic cancers require autophagy for tumor growth
    Shenghong Yang
    Division of Genomic Stability and DNA Repair, Department of Radiation Oncology, Dana Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts 02115, USA
    Genes Dev 25:717-29. 2011
    ....
  16. pmc Enzymatic targeting of the stroma ablates physical barriers to treatment of pancreatic ductal adenocarcinoma
    Paolo P Provenzano
    Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA 98109, USA
    Cancer Cell 21:418-29. 2012
    ..In combination with the standard chemotherapeutic, gemcitabine, the treatment permanently remodels the tumor microenvironment and consistently achieves objective tumor responses, resulting in a near doubling of overall survival...
  17. ncbi Drug resistance by evasion of antiangiogenic targeting of VEGF signaling in late-stage pancreatic islet tumors
    Oriol Casanovas
    Department of Biochemistry and Biophysics, Comprehensive Cancer Center, and Diabetes Center, University of California, San Francisco, San Francisco, California 94143, USA
    Cancer Cell 8:299-309. 2005
    ..These other proangiogenic signals are functionally implicated in the revascularization and regrowth of tumors in the evasion phase, as FGF blockade impairs progression in the face of VEGF inhibition...
  18. pmc Up-regulation of miR-200 and let-7 by natural agents leads to the reversal of epithelial-to-mesenchymal transition in gemcitabine-resistant pancreatic cancer cells
    Yiwei Li
    Department of Pathology, Barbara Ann Karmanos Cancer Institute, Wayne State University School of Medicine, Detroit, Michigan 48201, USA
    Cancer Res 69:6704-12. 2009
    ....
  19. ncbi Genetics and biology of pancreatic ductal adenocarcinoma
    Aram F Hezel
    Department of Medical Oncology, Dana Farber Cancer Institute, Boston, MA 02115, USA
    Genes Dev 20:1218-49. 2006
    ..This confluence of developments offers the opportunity for accelerated discovery and the future promise of improved treatment...
  20. pmc The pancreas cancer microenvironment
    Christine Feig
    Cambridge Research Institute, Cancer Research UK
    Clin Cancer Res 18:4266-76. 2012
    ..Here, we will review our current understanding of the PDA tumor microenvironment, and highlight opportunities for further exploration that may benefit patients...
  21. pmc CD40 agonists alter tumor stroma and show efficacy against pancreatic carcinoma in mice and humans
    Gregory L Beatty
    Abramson Family Cancer Research Institute, University of Pennsylvania School of Medicine, 421 Curie Boulevard, Philadelphia, PA 19104, USA
    Science 331:1612-6. 2011
    ..Thus, cancer immune surveillance does not necessarily depend on therapy-induced T cells; rather, our findings demonstrate a CD40-dependent mechanism for targeting tumor stroma in the treatment of cancer...
  22. pmc Gemcitabine plus nab-paclitaxel is an active regimen in patients with advanced pancreatic cancer: a phase I/II trial
    Daniel D Von Hoff
    TGen Virginia G Piper Cancer Ctr, 445 N Fifth St, Suite 600, Phoenix, AZ 85004, USA
    J Clin Oncol 29:4548-54. 2011
    ..Subsequent preclinical studies investigated the changes involving the pancreatic stroma and drug uptake...
  23. ncbi MicroRNA expression patterns to differentiate pancreatic adenocarcinoma from normal pancreas and chronic pancreatitis
    Mark Bloomston
    Division of Surgical Oncology, James Cancer Hospital and Solove Research Institute, Ohio State University, Columbus, USA
    JAMA 297:1901-8. 2007
    ..While global microRNA (miRNA) expression patterns of many embryologic, physiologic, and oncogenic processes have been described, description of the role of miRNAs in ductal adenocarcinoma of the pancreas is lacking...
  24. ncbi Epithelial to mesenchymal transition contributes to drug resistance in pancreatic cancer
    Thiruvengadam Arumugam
    Department of Cancer Biology, University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer Res 69:5820-8. 2009
    ..012). Therefore, our results suggest that Zeb-1 and other regulators of EMT may maintain drug resistance in human pancreatic cancer cells, and therapeutic strategies to inhibit Zeb-1 and reverse EMT should be evaluated...
  25. pmc Matrix metalloproteinase-9 triggers the angiogenic switch during carcinogenesis
    G Bergers
    Department of Biochemistry and Biophysics, University of California, 513 Parnassus Avenue, San Francisco, California 94143, USA
    Nat Cell Biol 2:737-44. 2000
    ..Absence of MMP-2 does not impair induction of angiogenesis, but retards tumour growth, whereas lack of urokinase has no effect. Our results show that MMP-9 is a component of the angiogenic switch...
  26. pmc Antidiabetic therapies affect risk of pancreatic cancer
    Donghui Li
    Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas 77030, USA
    Gastroenterology 137:482-8. 2009
    ..We investigated the effect of antidiabetic therapies on the risk of pancreatic cancer...
  27. pmc Hedgehog is an early and late mediator of pancreatic cancer tumorigenesis
    Sarah P Thayer
    Department of Surgery, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts 02114, USA
    Nature 425:851-6. 2003
    ..These data suggest that this pathway may have an early and critical role in the genesis of this cancer, and that maintenance of hedgehog signalling is important for aberrant proliferation and tumorigenesis...
  28. ncbi Gastroenteropancreatic neuroendocrine tumours
    Irvin M Modlin
    Department of Gastroenterological Surgery, Yale University, New Haven, CT 06520 8062, USA
    Lancet Oncol 9:61-72. 2008
    ..Progress is unlikely to occur without development of centers of excellence, with dedicated combined clinical teams to coordinate multicentre studies, maintain clinical and tissue databases, and refine molecularly targeted therapeutics...
  29. ncbi Adjuvant chemotherapy with gemcitabine vs observation in patients undergoing curative-intent resection of pancreatic cancer: a randomized controlled trial
    Helmut Oettle
    Department of Medical Oncology and Hematology, Charite School of Medicine, Campus Virchow Klinikum, Berlin, Germany
    JAMA 297:267-77. 2007
    ..The role of adjuvant therapy in resectable pancreatic cancer is still uncertain, and no recommended standard exists...
  30. pmc miR-146a suppresses invasion of pancreatic cancer cells
    Yiwei Li
    Departments of Pathology and Internal Medicine, Barbara Ann Karmanos Cancer Institute, Wayne State University School of Medicine, Detroit, Michigan 48201, USA
    Cancer Res 70:1486-95. 2010
    ..Our findings reveal DIM and isoflavone as nontoxic activators of a miRNA that can block pancreatic cancer cell invasion and metastasis, offering starting points to design novel anticancer agents...
  31. ncbi DPC4, a candidate tumor suppressor gene at human chromosome 18q21.1
    S A Hahn
    Department of Pathology, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA
    Science 271:350-3. 1996
    ..1. These results identify DPC4 as a candidate tumor suppressor gene whose inactivation may play a role in pancreatic and possibly other human cancers...
  32. pmc Activated Kras and Ink4a/Arf deficiency cooperate to produce metastatic pancreatic ductal adenocarcinoma
    Andrew J Aguirre
    Department of Medical Oncology, Dana Farber Cancer Institute and Department of Genetics, Harvard Medical School, Boston, MA 02115, USA
    Genes Dev 17:3112-26. 2003
    ..This faithful mouse model may permit the systematic analysis of genetic lesions implicated in the human disease and serve as a platform for the identification of early disease markers and for the efficient testing of novel therapies...
  33. ncbi Elevated expression of microRNAs 155, 203, 210 and 222 in pancreatic tumors is associated with poorer survival
    Thomas Greither
    Clinic of Radiation Therapy, Martin Luther University, Halle, Wittenberg, Germany
    Int J Cancer 126:73-80. 2010
    ..Furthermore, the putative target genes for these microRNAs suggest a complex signaling network that can affect PDAC tumorigenesis and tumor progression...
  34. pmc EGF receptor is required for KRAS-induced pancreatic tumorigenesis
    Christine M Ardito
    Department of Pharmacological Sciences, Stony Brook University, Stony Brook, NY 11794, USA
    Cancer Cell 22:304-17. 2012
    ..Without EGFR activity, active RAS levels are not sufficient to induce robust MEK/ERK activity, a requirement for epithelial transformation...
  35. pmc Tumor-derived granulocyte-macrophage colony-stimulating factor regulates myeloid inflammation and T cell immunity in pancreatic cancer
    Lauren J Bayne
    Abramson Family Cancer Research Institute, University of Pennsylvania School of Medicine, Philadelphia, PA 19104, USA
    Cancer Cell 21:822-35. 2012
    ..In humans, PDA tumor cells prominently expressed GM-CSF in vivo. Thus, tumor-derived GM-CSF is an important regulator of inflammation and immune suppression within the tumor microenvironment...
  36. pmc Expression profiling identifies microRNA signature in pancreatic cancer
    Eun Joo Lee
    College of Pharmacy, Ohio State University, Columbus, OH 43210, USA
    Int J Cancer 120:1046-54. 2007
    ..Aberrant microRNA expression may offer new clues to pancreatic tumorigenesis and may provide diagnostic biomarkers for pancreatic adenocarcinoma...
  37. pmc MicroRNA miR-34 inhibits human pancreatic cancer tumor-initiating cells
    Qing Ji
    Department of Radiation Oncolog, University of Michigan, Ann Arbor, Michigan, United States of America
    PLoS ONE 4:e6816. 2009
    ..Among the target proteins regulated by miR-34 are Notch pathway proteins and Bcl-2, suggesting the possibility of a role for miR-34 in the maintenance and survival of cancer stem cells...
  38. pmc Cancer-associated stromal fibroblasts promote pancreatic tumor progression
    Rosa F Hwang
    Department of Surgical Oncology, The University of Texas M D Anderson Cancer Center, Houston, Texas 77230 1402, USA
    Cancer Res 68:918-26. 2008
    ..These data indicate that stellate cells have an important role in supporting and promoting pancreatic cancer. Identification of HPSC-derived factors may lead to novel stroma-targeted therapies for pancreatic cancer...
  39. ncbi Prevalence of FOXP3+ regulatory T cells increases during the progression of pancreatic ductal adenocarcinoma and its premalignant lesions
    Nobuyoshi Hiraoka
    Pathology Division, National Cancer Center Research Institute and Division of Hepatobiliary and Pancreatic Surgery, National Cancer Center Central Hospital, Tokyo, Japan
    Clin Cancer Res 12:5423-34. 2006
    ..The aim of this study was to investigate the clinical significance and roles of TR in the progression and multistep carcinogenesis of pancreatic ductal adenocarcinoma...
  40. ncbi miRNA-96 suppresses KRAS and functions as a tumor suppressor gene in pancreatic cancer
    Shuangni Yu
    Department of Pathology, Peking Union Medical College Hospital, Tsinghua University, Beijing, PR China
    Cancer Res 70:6015-25. 2010
    ..Our findings identify miR-96 as a potent regulator of KRAS, which may provide a novel therapeutic strategy for treatment of pancreatic cancer and other KRAS-driven cancers...
  41. pmc Pancreatic cancer
    Anirban Maitra
    Department of Pathology, The Sol Goldman Pancreatic Cancer Research Center, Johns Hopkins University School of Medicine, Baltimore, MD 21231, USA
    Annu Rev Pathol 3:157-88. 2008
    ....
  42. pmc A gene expression signature associated with "K-Ras addiction" reveals regulators of EMT and tumor cell survival
    Anurag Singh
    Veterans Affairs Palo Alto Healthcare System, Palo Alto, CA 94306, USA
    Cancer Cell 15:489-500. 2009
    ..These findings indicate that epithelial differentiation and tumor cell viability are associated, and that EMT regulators in "K-Ras-addicted" cancers represent candidate therapeutic targets...
  43. pmc Gemcitabine sensitivity can be induced in pancreatic cancer cells through modulation of miR-200 and miR-21 expression by curcumin or its analogue CDF
    Shadan Ali
    Division of Hematology Oncology, Department of Pathology, Karmanos Cancer Institute, Wayne State University, Detroit, Michigan 48201, USA
    Cancer Res 70:3606-17. 2010
    ..These results prompt further interest in CDF as a drug modality to improve treatment outcome of patients diagnosed with PC as a result of its greater bioavailability in pancreatic tissue...
  44. ncbi Phase III randomized comparison of gemcitabine versus gemcitabine plus capecitabine in patients with advanced pancreatic cancer
    David Cunningham
    Royal Marsden National HealthService NHS Foundation Trust, London and Surrey, United Kingdom
    J Clin Oncol 27:5513-8. 2009
    ..This open-label study was designed to compare the overall survival (OS) of patients randomly assigned to GEM alone or GEM plus capecitabine (GEM-CAP)...
  45. ncbi Daily oral everolimus activity in patients with metastatic pancreatic neuroendocrine tumors after failure of cytotoxic chemotherapy: a phase II trial
    James C Yao
    Department of Gastrointestinal Medical Oncology, The University of Texas M D Anderson Cancer Center, 1515 Holcombe Blvd, Unit 426, Houston, TX 77030, USA
    J Clin Oncol 28:69-76. 2010
    ....
  46. ncbi New biomarkers and targets in pancreatic cancer and their application to treatment
    Eithne Costello
    National Institute for Health Research Pancreas Biomedical Research Unit and Liverpool Cancer Research UK Centre, Department of Molecular, University of Liverpool, Liverpool, L69 3GA, UK
    Nat Rev Gastroenterol Hepatol 9:435-44. 2012
    ..We provide an overview of current treatments and, finally, we discuss novel therapeutic approaches, including the role of biomarkers in therapy for pancreatic cancer...
  47. ncbi MicroRNA expression alterations are linked to tumorigenesis and non-neoplastic processes in pancreatic ductal adenocarcinoma
    A E Szafranska
    Asuragen Inc, Austin, Woodward, TX 78744, USA
    Oncogene 26:4442-52. 2007
    ..Our data provides novel insights into the miRNA-driven pathophysiological mechanisms involved in PDAC development and offers new candidate targets to be exploited both for diagnostic and therapeutic strategies...
  48. ncbi Pancreatic cancer biology and genetics
    Nabeel Bardeesy
    Department of Adult Oncology, Dana Farber Cancer Institute and Departments of Medicine and Genetics, Harvard Medical School, Boston, Massachusetts 02115, USA
    Nat Rev Cancer 2:897-909. 2002
    ....
  49. ncbi Chronic pancreatitis is essential for induction of pancreatic ductal adenocarcinoma by K-Ras oncogenes in adult mice
    Carmen Guerra
    Molecular Oncology Program, Centro Nacional de Investigaciones Oncologicas, E 28029 Madrid, Spain
    Cancer Cell 11:291-302. 2007
    ..These observations suggest that, during adulthood, PDA stems from a combination of genetic (e.g., somatic K-Ras mutations) and nongenetic (e.g., tissue damage) events...
  50. pmc GLI1 is regulated through Smoothened-independent mechanisms in neoplastic pancreatic ducts and mediates PDAC cell survival and transformation
    Olivier Nolan-Stevaux
    Helen Diller Family Comprehensive Cancer Center, University of California at San Francisco, San Francisco, California 94143, USA
    Genes Dev 23:24-36. 2009
    ....
  51. pmc Subtypes of pancreatic ductal adenocarcinoma and their differing responses to therapy
    Eric A Collisson
    Life Sciences Division, Lawrence Berkeley National Laboratory, Berkeley, California, USA
    Nat Med 17:500-3. 2011
    ..We further define gene signatures for these subtypes that may have utility in stratifying patients for treatment and present preclinical model systems that may be used to identify new subtype specific therapies...
  52. ncbi Advanced pancreatic carcinoma: current treatment and future challenges
    Anastasios Stathis
    Division of Medical Oncology and Hematology, Department of Medicine, Princess Margaret Hospital, University of Toronto, Toronto, ON M5G 2M9, Canada
    Nat Rev Clin Oncol 7:163-72. 2010
    ..We review the current standards of care for patients with locally advanced and metastatic pancreatic carcinoma and outline some future directions for the development of new treatment strategies...
  53. ncbi MicroRNA expression abnormalities in pancreatic endocrine and acinar tumors are associated with distinctive pathologic features and clinical behavior
    Claudia Roldo
    Department of Molecular Virology, Immunology and Medical Genetics and Comprehensive Cancer Center, Ohio State University, Columbus, OH, USA
    J Clin Oncol 24:4677-84. 2006
    ..Recent evidence indicates that microRNAs can contribute to tumor development and progression and may have diagnostic and prognostic value in several human malignancies...
  54. pmc MicroRNA-150 directly targets MUC4 and suppresses growth and malignant behavior of pancreatic cancer cells
    Sanjeev K Srivastava
    Department of Oncologic Sciences, Mitchell Cancer Institute, University of South Alabama, 1660 Springhill Avenue, Mobile, AL 36604 1405, USA
    Carcinogenesis 32:1832-9. 2011
    ..Altogether, these findings establish miR-150 as a novel regulator of MUC4 and a tumor suppressor miRNA in PC...
  55. ncbi Stromal biology and therapy in pancreatic cancer
    Albrecht Neesse
    Li Ka Shing Centre, Cambridge Research Institute, Cancer Research UK, Cambridge, UK
    Gut 60:861-8. 2011
    ....
  56. pmc Restitution of tumor suppressor microRNAs using a systemic nanovector inhibits pancreatic cancer growth in mice
    Dipankar Pramanik
    The Sol Goldman Pancreatic Cancer Research Center, Johns Hopkins University School of Medicine, Baltimore, MD 21231, USA
    Mol Cancer Ther 10:1470-80. 2011
    ..The nanovector is a platform with potential broad applicability in systemic miRNA delivery to cancer cells...
  57. ncbi Dynamics of the immune reaction to pancreatic cancer from inception to invasion
    CAROLYN E CLARK
    Abramson Family Cancer Research Institute, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania, USA
    Cancer Res 67:9518-27. 2007
    ..Efforts to test potent inhibitors of MDSC, tumor-associated macrophages, and Treg, particularly early in the disease represent important next steps for developing novel immunotherapy of cancer...
  58. pmc Gemcitabine plus bevacizumab compared with gemcitabine plus placebo in patients with advanced pancreatic cancer: phase III trial of the Cancer and Leukemia Group B (CALGB 80303)
    Hedy Lee Kindler
    University of Chicago Cancer Research Center, Chicago, IL 60637 1470, USA
    J Clin Oncol 28:3617-22. 2010
    ..These encouraging data led Cancer and Leukemia Group B (CALGB) to conduct a double-blind, placebo-controlled, randomized phase III trial of gemcitabine/bevacizumab versus gemcitabine/placebo in advanced pancreatic cancer patients...
  59. ncbi Diabetes mellitus and risk of pancreatic cancer: A meta-analysis of cohort studies
    Qiwen Ben
    Department of Gastroenterology, Changhai Hospital of Second Military Medical University, Shanghai, China
    Eur J Cancer 47:1928-37. 2011
    ..We examined this association by conducting a detailed meta-analysis of cohort studies...
  60. ncbi Stromal biology of pancreatic cancer
    Gerald C Chu
    Department of Medical Oncology, Dana Farber Cancer Institute, Boston, MA, USA
    J Cell Biochem 101:887-907. 2007
    ..Such knowledge may be used to understand the evolution and biology of this lethal cancer and may convert these insights into new points of therapeutic intervention...
  61. ncbi The role of obesity and related metabolic disturbances in cancers of the colon, prostate, and pancreas
    Edward Giovannucci
    Department of Nutrition, Harvard School of Public Health, Boston, Massachusetts, USA
    Gastroenterology 132:2208-25. 2007
    ..The mechanisms for these associations, however, remain speculative and deserve further study. Hyperinsulinemia may be important, but the role of oxidative stress initiated by hyperglycemia also deserves further attention...
  62. ncbi Most human carcinomas of the exocrine pancreas contain mutant c-K-ras genes
    C Almoguera
    Department of Biochemistry, State University of New York, Stony Brook 11794
    Cell 53:549-54. 1988
    ..We conclude from these results that c-K-ras somatic mutational activation is a critical event in the oncogenesis of most, if not all, human cancers of the exocrine pancreas...
  63. pmc The pancreatic stellate cell: a star on the rise in pancreatic diseases
    M Bishr Omary
    Department of Medicine, VA Palo Alto Health Care System, Palo Alto, California 94304, USA
    J Clin Invest 117:50-9. 2007
    ..Therefore, understanding the biology of PaSCs offers potential therapeutic targets for the treatment and prevention of these diseases...
  64. pmc Acquisition of epithelial-mesenchymal transition phenotype of gemcitabine-resistant pancreatic cancer cells is linked with activation of the notch signaling pathway
    Zhiwei Wang
    Department of Pathology, Karmanos Cancer Institute, Wayne State University, Detroit, Michigan, USA
    Cancer Res 69:2400-7. 2009
    ....
  65. ncbi International consensus guidelines for management of intraductal papillary mucinous neoplasms and mucinous cystic neoplasms of the pancreas
    Masao Tanaka
    Department of Surgery and Oncology, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan
    Pancreatology 6:17-32. 2006
    ..The proposed guidelines represent a consensus of the working group of the International Association of Pancreatology...
  66. ncbi ras oncogenes in human cancer: a review
    J L Bos
    Laboratory for Molecular Carcinogenesis, Sylvius Laboratory, Leiden, The Netherlands
    Cancer Res 49:4682-9. 1989
    ..There is some evidence that environmental agents may be involved in the induction of the mutations...
  67. pmc Blockade of hedgehog signaling inhibits pancreatic cancer invasion and metastases: a new paradigm for combination therapy in solid cancers
    Georg Feldmann
    Department of Pathology, Johns Hopkins University School of Medicine, 1550 Orleans Street, Baltimore, MD 21231, USA
    Cancer Res 67:2187-96. 2007
    ....
  68. pmc KrasG12D-induced IKK2/β/NF-κB activation by IL-1α and p62 feedforward loops is required for development of pancreatic ductal adenocarcinoma
    Jianhua Ling
    Department of Molecular and Cellular Oncology, The University of Texas M D Anderson Cancer Centre, Houston, 77030, USA
    Cancer Cell 21:105-20. 2012
    ..Therefore, our findings demonstrate the mechanism by which IKK2/β/NF-κB is activated by Kras(G12D) through dual feedforward loops of IL-1α/p62...
  69. ncbi Notch mediates TGF alpha-induced changes in epithelial differentiation during pancreatic tumorigenesis
    Yoshiharu Miyamoto
    Departments of Surgery, Oncology, and Pathology, The Sidney Kimmel Cancer Center at Johns Hopkins, Johns Hopkins University School of Medicine, Baltimore, MD 21287, USA
    Cancer Cell 3:565-76. 2003
    ..These findings suggest that Notch mediates the tumor-initiating effects of TG alpha by expanding a population of undifferentiated precursor cells...
  70. pmc FKBP51 affects cancer cell response to chemotherapy by negatively regulating Akt
    Huadong Pei
    Division of Oncology Research, Department of Oncology, Mayo Clinic, Rochester, MN 55905, USA
    Cancer Cell 16:259-66. 2009
    ..Overall, our findings identify FKBP51 as a negative regulator of the Akt pathway, with potentially important implications for cancer etiology and response to chemotherapy...
  71. pmc MicroRNA-21 is overexpressed in pancreatic cancer and a potential predictor of survival
    Mary Dillhoff
    Department of Surgery, The Ohio State University, 410 W 10th Ave, N924 Doan Hall, Columbus, OH 43210, USA
    J Gastrointest Surg 12:2171-6. 2008
    ..We sought to determine the expression pattern of miR-21 in pancreatic cancers and its impact on clinicopathologic characteristics...
  72. pmc Type-II diabetes and pancreatic cancer: a meta-analysis of 36 studies
    R Huxley
    The George Institute for International Health, The University of Sydney, PO Box M201, Missenden Road, Sydney NSW 2050, Australia
    Br J Cancer 92:2076-83. 2005
    ..1 vs 1.5; P=0.005). These results support a modest causal association between type-II diabetes and pancreatic cancer...
  73. ncbi Stat3/Socs3 activation by IL-6 transsignaling promotes progression of pancreatic intraepithelial neoplasia and development of pancreatic cancer
    Marina Lesina
    II Medizinische Klinik, Klinikum rechts der Isar, Technische Universitat Munchen, Munich, Germany
    Cancer Cell 19:456-69. 2011
    ..Our data describe the involvement of IL-6 transsignaling/Stat3/Socs3 in PanIN progression and PDAC development...
  74. pmc Gemcitabine alone versus gemcitabine plus radiotherapy in patients with locally advanced pancreatic cancer: an Eastern Cooperative Oncology Group trial
    Patrick J Loehrer
    Indiana University Melvin and Bren Simon Cancer Center, 980 West Walnut St, Suite C528, Indianapolis, IN 46202, USA
    J Clin Oncol 29:4105-12. 2011
    ..The purpose of this trial was to evaluate the role of radiation therapy with concurrent gemcitabine (GEM) compared with GEM alone in patients with localized unresectable pancreatic cancer...
  75. ncbi Adjuvant chemotherapy with fluorouracil plus folinic acid vs gemcitabine following pancreatic cancer resection: a randomized controlled trial
    John P Neoptolemos
    Liverpool Cancer Research UK Cancer Trials Unit, Cancer Research UK Centre, University of Liverpool, Fifth Floor, UCD Bldg, Daulby Street, Liverpool, L69 3GA, United Kingdom
    JAMA 304:1073-81. 2010
    ..Gemcitabine is known to be the most effective agent in advanced disease as well as an effective agent in patients with resected pancreatic cancer...
  76. ncbi Tissue biomarkers for prognosis in pancreatic ductal adenocarcinoma: a systematic review and meta-analysis
    Nigel B Jamieson
    West of Scotland Pancreatic Unit and Department of Pathology, Glasgow Royal Infirmary, Alexandra Parade, Glasgow, United Kingdom
    Clin Cancer Res 17:3316-31. 2011
    ....
  77. ncbi Tumor microenvironment and progression of pancreatic cancer
    M Erkan
    Department of Surgery, Technische Universitat Munchen, Ismaningerstrasse 22, Munich 81675, Germany
    Exp Oncol 32:128-31. 2010
    ..The common denominator of all these conditions is; chronic inflammation leads to increased incidence of cancer. In this review the impact of the activated stroma on pancreatic carcinogenesis is discussed...
  78. ncbi Treatment for pancreatic cancer: current therapy and continued progress
    A Craig Lockhart
    Department of Medicine, Division of Hematology Oncology, Vanderbilt University, Medical Center, Nashville, Tennessee 37232 6307, USA
    Gastroenterology 128:1642-54. 2005
    ..This article will summarize the data that has led to the current standards of therapy for patients with resectable and advanced pancreatic cancer and review new treatment strategies for this disease...
  79. ncbi Role of NF-kappaB and Akt/PI3K in the resistance of pancreatic carcinoma cell lines against gemcitabine-induced cell death
    Alexander Arlt
    1Laboratory of Molecular Gastroenterology and Hepatology, 1st Department of Medicine, University of Kiel, Germany
    Oncogene 22:3243-51. 2003
    ....
  80. ncbi Influence of resection margins and treatment on survival in patients with pancreatic cancer: meta-analysis of randomized controlled trials
    Giovanni Butturini
    Division of Surgery and Oncology, School of Cancer Studies, Royal Liverpool University Hospital, 5th Floor, UCD Bldg, Daulby St, Liverpool L69 3GA, England
    Arch Surg 143:75-83; discussion 83. 2008
    ..To assess the influence of resection margins and adjuvant chemoradiotherapy or chemotherapy on survival for patients with pancreatic cancer by meta-analysis of individual data from randomized controlled trials...
  81. ncbi First-line chemotherapy with capecitabine and temozolomide in patients with metastatic pancreatic endocrine carcinomas
    Jonathan R Strosberg
    Department of Gastrointestinal Oncology, H Lee Moffitt Cancer Center and Research Institute, Tampa, Florida 33612, USA
    Cancer 117:268-75. 2011
    ..The authors retrospectively evaluated the efficacy of capecitabine and temozolomide in 30 patients with metastatic pancreatic endocrine carcinomas to assess response rate, progression free survival (PFS), and overall survival (OS)...
  82. pmc Phase III study comparing gemcitabine plus cetuximab versus gemcitabine in patients with advanced pancreatic adenocarcinoma: Southwest Oncology Group-directed intergroup trial S0205
    Philip A Philip
    Wayne State University, Karmanos Cancer Institute, GI Oncology, Detroit, MI 48201, USA
    J Clin Oncol 28:3605-10. 2010
    ..This trial was conducted to evaluate the contribution of an EGFR-targeted agent to standard gemcitabine therapy. Cetuximab is a monoclonal antibody against the ligand-binding domain of the receptor...
  83. pmc Inhibiting Cxcr2 disrupts tumor-stromal interactions and improves survival in a mouse model of pancreatic ductal adenocarcinoma
    Hideaki Ijichi
    Department of Gastroenterology, Graduate School of Medicine, University of Tokyo, Tokyo, Japan
    J Clin Invest 121:4106-17. 2011
    ..Further, our results suggest that inhibiting tumor-stromal interactions might be a promising therapeutic strategy for PDAC...
  84. ncbi Phase III trial of bevacizumab in combination with gemcitabine and erlotinib in patients with metastatic pancreatic cancer
    Eric Van Cutsem
    University Hospital Gasthuisberg Leuven, Digestive Oncology Unit, Herestraat 49, B 3000 Leuven, Belgium
    J Clin Oncol 27:2231-7. 2009
    ..Phase II results for bevacizumab plus gemcitabine provided the rationale for a phase III trial of gemcitabine-erlotinib plus bevacizumab or placebo...
  85. ncbi Best supportive care (BSC) versus oxaliplatin, folinic acid and 5-fluorouracil (OFF) plus BSC in patients for second-line advanced pancreatic cancer: a phase III-study from the German CONKO-study group
    Uwe Pelzer
    Universitatsmedizin Berlin Charite, Centrum für Tumormedizin, Augustenburger Platz 1, 13353 Berlin, Germany
    Eur J Cancer 47:1676-81. 2011
    ..We initiated a phase III multicentre study comparing OFF versus best supportive care (BSC) in patients with APC progressing while on gemcitabine therapy...
  86. pmc Resveratrol inhibits pancreatic cancer stem cell characteristics in human and KrasG12D transgenic mice by inhibiting pluripotency maintaining factors and epithelial-mesenchymal transition
    Sharmila Shankar
    Department of Pathology and Laboratory Medicine, The University of Kansas Cancer Center, The University of Kansas Medical Center, Kansas City, Kansas, United States of America
    PLoS ONE 6:e16530. 2011
    ..The objectives of this study were to examine the molecular mechanisms by which resveratrol inhibits stem cell characteristics of pancreatic CSCs derived from human primary tumors and Kras(G12D) transgenic mice...
  87. ncbi Down-regulation of notch-1 inhibits invasion by inactivation of nuclear factor-kappaB, vascular endothelial growth factor, and matrix metalloproteinase-9 in pancreatic cancer cells
    Zhiwei Wang
    Department of Pathology, Karmanos Cancer Institute, Wayne State University School of Medicine, Detroit, Michigan 48201, USA
    Cancer Res 66:2778-84. 2006
    ....
  88. ncbi A randomized trial of chemoradiotherapy and chemotherapy after resection of pancreatic cancer
    John P Neoptolemos
    Department of Surgery, Liverpool University, Liverpool, United Kingdom
    N Engl J Med 350:1200-10. 2004
    ..The effect of adjuvant treatment on survival in pancreatic cancer is unclear. We report the final results of the European Study Group for Pancreatic Cancer 1 Trial and update the interim results...
  89. pmc Role of pancreatic stellate cells in pancreatic cancer metastasis
    Zhihong Xu
    Pancreatic Research Group, South Western Sydney Clinical School, School of Medical Sciences, Faculty of Medicine, Room 505, Level 5, Wallace Wurth Building, The University of New South Wales, Sydney, NSW 2052, Australia
    Am J Pathol 177:2585-96. 2010
    ..Human PSCs accompany cancer cells to metastatic sites, stimulate angiogenesis, and are able to intravasate/extravasate to and from blood vessels...
  90. pmc Type 2 diabetes increases and metformin reduces total, colorectal, liver and pancreatic cancer incidences in Taiwanese: a representative population prospective cohort study of 800,000 individuals
    Meei Shyuan Lee
    School of Public Health, National Defense Medical Center, Taipei, ROC
    BMC Cancer 11:20. 2011
    ..Metformin protection against cancer risk in Orientals is uncertain. We examined the possible metformin effect on total, esophageal, gastric, colorectal (CRC), hepatocellular (HCC) and pancreatic cancers in a Taiwanese cohort...
  91. ncbi Neuroendocrine tumors of the pancreas
    Florian Ehehalt
    Department for General, Thoracic and Vascular Surgery, University Hospital Carl Gustav Carus, University of Technology, Fetscherstrasse 74, Dresden, Germany
    Oncologist 14:456-67. 2009
    ..Surgery remains the primary therapeutic option for patients with PNETs. Research on PNETs is desperately needed to improve the therapeutic options for patients with this disease...
  92. ncbi Combined targeted treatment to eliminate tumorigenic cancer stem cells in human pancreatic cancer
    Maria Theresa Mueller
    Clinical Research Programme, Spanish National Cancer Research Centre CNIO, Madrid, Spain
    Gastroenterology 137:1102-13. 2009
    ..Signaling through sonic hedgehog and mammalian target of rapamycin (mTOR), respectively, may be essential for CSC self-renewal and could represent putative targets for novel treatment modalities...
  93. pmc KRAS, Hedgehog, Wnt and the twisted developmental biology of pancreatic ductal adenocarcinoma
    John P Morris
    Diabetes Center, University of California, San Francisco, 513 Parnassus Ave, San Francisco, California 94143, USA
    Nat Rev Cancer 10:683-95. 2010
    ..Here we examine the central part that KRAS plays in the biology of PDAC, and how the timing and location of Hh and Wnt-β-catenin signalling dictate the specification and oncogenic properties of PDAC...
  94. ncbi Diabetes and pancreatic cancer: chicken or egg?
    J Trent Magruder
    Department of Surgery, Johns Hopkins University School of Medicine, Johns Hopkins Bayview Medical Center, Baltimore, MD, USA
    Pancreas 40:339-51. 2011
    ..Although half of all patients with pancreatic cancer are diabetic at the time of diagnosis, it remains unclear whether the diabetes associated with pancreatic cancer is a cause or an effect of the malignancy...
  95. ncbi Fluorouracil, doxorubicin, and streptozocin in the treatment of patients with locally advanced and metastatic pancreatic endocrine carcinomas
    Maria A Kouvaraki
    Department of Surgical Oncology, The University of Texas M D Anderson Cancer Center, Houston, TX, USA
    J Clin Oncol 22:4762-71. 2004
    ....
  96. pmc MicroRNA dynamics in the stages of tumorigenesis correlate with hallmark capabilities of cancer
    Peter Olson
    Diabetes Center, University of California at San Francisco, San Francisco, California 94143, USA
    Genes Dev 23:2152-65. 2009
    ..Many of the miR changes associated with specific stages and hallmark capabilities in the mouse model are similarly altered in human tumors, including cognate pancreatic neuroendocrine tumors, implying a generality...
  97. ncbi Liver transplantation for gastroenteropancreatic neuroendocrine cancers: Defining selection criteria to improve survival
    Frederike G I van Vilsteren
    Mayo Clinic College of Medicine, Rochester, MN 55905, USA
    Liver Transpl 12:448-56. 2006
    ..In conclusion, liver transplantation for patients with hepatic metastases from GEP is a viable therapeutic option in highly selected patients...
  98. ncbi Gli1 contributes to the invasiveness of pancreatic cancer through matrix metalloproteinase-9 activation
    Shuntaro Nagai
    Department of Cancer Therapy and Research, Graduate School of Medical Sciences, Kyushu University, 3 1 1 Maidashi, Higashi ku, Fukuoka 812 8582, Japan
    Cancer Sci 99:1377-84. 2008
    ..Taken together, these findings suggest that members of the Hh pathway, especially Gli1, play an important role in the invasiveness of pancreatic cancer cells through the regulation of MMP-9 expression...
  99. ncbi Pancreatic cancer stem cells
    Cheong J Lee
    Department of Surgery, University of Michigan, Ann Arbor, MI 48109, USA
    J Clin Oncol 26:2806-12. 2008
    ..Understanding the biologic behavior and the molecular pathways that regulate growth, survival, and metastasis of pancreatic CSCs will help to identify novel therapeutic approaches to treat this dismal disease...
  100. pmc Ligand-dependent Notch signaling is involved in tumor initiation and tumor maintenance in pancreatic cancer
    Michael E Mullendore
    Department of Pathology, The Sol Goldman Pancreatic Cancer Research Center, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA
    Clin Cancer Res 15:2291-301. 2009
    ..Aberrant activation of the Notch signaling pathway is commonly observed in human pancreatic cancer, although the mechanism(s) for this activation has not been elucidated...
  101. pmc DPC4 gene status of the primary carcinoma correlates with patterns of failure in patients with pancreatic cancer
    Christine A Iacobuzio-Donahue
    Department of Pathology, Surgery, and Oncology, The Sol Goldman Pancreatic Cancer Research Center, Johns Hopkins Medical Institutions, Baltimore, MD 21231, USA
    J Clin Oncol 27:1806-13. 2009
    ..A comprehensive study of pancreatic cancers from patients who have succumbed to their disease has the potential to greatly expand our understanding of the most lethal stage of this disease and identify novel areas for intervention...

Research Grants63

  1. Neuronal mRNA PET Imaging
    Eric Wickstrom; Fiscal Year: 2010
    ..In the future, beyond the scope of this proposal, nuclear medicine imaging of brain cell gene activity in humans might explain why some individuals become addicted more easily than others. ..
  2. Cx43 phosphorylation modulates Kras mediated pancreas cancer progression
    Paul D Lampe; Fiscal Year: 2012
    ..Since drugs that affect Cx43 activity and gap junctional communication are under development, understanding how these factors affect progression could ultimately lead to better treatment of this lethal disease. ..
  3. ASCORBATE-INDUCED RADIOSENSITIZATION IN PANCREATIC CANCER
    Joseph J Cullen; Fiscal Year: 2013
    ....
  4. Using Ketogenic Diets to Enhance Radio-Chemo-Therapy Response: A Phase I Trial
    DOUGLAS ROBERT SPITZ; Fiscal Year: 2012
    ....
  5. PET Imaging of KRAS2 Activation to Guide EGFR Targeting in Cancer Therapy
    Eric Wickstrom; Fiscal Year: 2013
    ....
  6. Communication in Late-stage Cancer: Exploring Hospice Decision
    DEBORAH PEASE WALDROP; Fiscal Year: 2010
    ..3) Understanding how end-of-life decisions are made is essential for the efficient planning and delivery of comprehensive services for the growing number of adults who will die from cancer. ..
  7. Phenotyping pain in a mouse model of pancreatic cancer
    Brian M Davis; Fiscal Year: 2012
    ..This nerve-cancer interaction may also contribute to the aggressive behavior of pancreatic neoplasms. Together these findings suggest an intimate relationship between the peripheral nervous system and ..
  8. Radiohybridization Imaging of HER2 Oncogene to Detect Breast Cancer
    Eric Wickstrom; Fiscal Year: 2010
    ..In the future, imaging multiple breast cancer genes might diagnose estrogen-dependent vs. estrogen-independent breast cancer without an invasive procedure. ..
  9. Case Control Study of Pancreas Cancer in Shanghai, China
    Harvey A Risch; Fiscal Year: 2012
    ..In addition to reduction of cigarette smoking, Helicobacter and dietary factors are modifiable and could be involved in a program to reduce risk of pancreas cancer. ..
  10. CCR2 BLOCKADE IN HUMAN PANCREATIC CANCER
    David C Linehan; Fiscal Year: 2013
    ..Finally, optimal integration of CCR2 blockade with chemotherapy will be assessed in Aim 4 to allow for the rational design of combination therapy in subsequent clinical trials. ..
  11. Population-Based Assessment of Cancer Trial Generalizability in the Elderly
    Elizabeth B Lamont; Fiscal Year: 2012
    ....
  12. Cytoskeletal Dynamics in Pancreatic Cancer Metastasis
    MARK A MC NIVEN; Fiscal Year: 2013
    ..Tumors of ductular origin comprise 95% of pancreatic neoplasms and have strong tendencies to invade surrounding parenchyma and metastasize to distal organs...
  13. Exploration of a Mutant p53 Reactivating Compound
    DARREN RICHARD CARPIZO; Fiscal Year: 2013
    ..3) Didactics: Dr. Carpizo will take attend several courses at Cold Spring Harbor including 1) Advanced Sequencing Technologies, and 2) Mechanisms and Models of Cancer and 3) Workshop on Pancreatic Cancer. ..
  14. A novel murine model for metastatic islet cell pancreas cancer
    Kenneth W Gross; Fiscal Year: 2013
    ..Overall, these data will result in a newly characterized model of metastatic pancreas cancer that can be used for testing of novel therapeutics and will contribute to a more complete understanding of islet cell cancers. ..
  15. Using Markers to Improve Pancreatic Cancer Screening
    Michael G Goggins; Fiscal Year: 2013
    ..We will enroll a new older-age high-risk cohort (age >55) and continue surveillance of patients enrolled in prior CAPS trials. ..
  16. Overcoming stromal barriers to therapeutics in pancreas cancer
    Sunil R Hingorani; Fiscal Year: 2013
    ..We will also test the ability of combining strategies directed against the stromal and epithelial compartments to make a clinically significant impact against this lethal disease. ..
  17. Pancreas cancer combination therapy based on stromal modulators and nano-carriers
    Robert M Straubinger; Fiscal Year: 2013
    ....
  18. Multi-Center Study of Pancreatic Cancer Etiology
    MARGARET MANDELSON; Fiscal Year: 2009
    ..abstract_text> ..
  19. Mechanisms of Murine Turmor Eradication by Immunotherapy
    Philip D Greenberg; Fiscal Year: 2013
    ....
  20. Stromal Periostin in Pancreatitis and Pancreas Cancer
    Rosa F Hwang; Fiscal Year: 2013
    ..A better understanding of the tumor-associated stroma may provide novel targets for treatment of pancreatic cancer. ..
  21. Theranostic Nano particles for Targeted Treatment of Pancreatic Cancer
    Lily Yang; Fiscal Year: 2013
    ..RELEVANCE (See instructions);This research project will develop novel tumor targeted nanotechnology therapeutics for improving the treatment of pancreas cancer. ..
  22. Antibody bead array technology for diagnosis of pre-invasive pancreatic cancer
    Peter Allen; Fiscal Year: 2012
    ....
  23. Mechanism-Based Use of Chk1 Inhibitors in Pancreas Cancer
    Jonathan Maybaum; Fiscal Year: 2013
    ..Also, we hypothesize that AZD7762 will inhibit Chk1 activity in surrogate normal tissues when administered at the MTD, and, possibly, at lower doses. ..
  24. Targeting RAS signaling with CDK and AKT inhibition in pancreatic cancer
    Nilofer Azad; Fiscal Year: 2013
    ..Our goal is to increase the survival of patients with pancreatic cancer by providing a new treatment option for this lethal disease. ..
  25. MRI-guided Ultrasonic Ablation of Pancreatic Cancer
    FRANK GRAHAM SOMMER; Fiscal Year: 2010
    ..If successful, the technique could be of great importance in providing meaningful treatment for a devastating disease for which there is no current effective treatment. ..
  26. Genetic progression of pancreatic mucinous cystic neoplasms to invasive carcinoma
    Sunil R Hingorani; Fiscal Year: 2013
    ..We have developed genetically engineered animal models of distinct types of pancreas cancer that together should help us identify unique points of vulnerability for the development of new treatments. ..
  27. Stat3 Signaling in Pancreas Cancer
    Nipun B Merchant; Fiscal Year: 2013
    ....
  28. NON-GASTRIN ACID SECRETAGOGUE IN ISLET CELL TUMORS
    William Chey; Fiscal Year: 1990
    ..In both pancreatic neoplasms and plasmas of these patients we found a non-gastrin acid secretagogue (NGAS) activity which appears to be ..
  29. BIOMEDICAL (BASIC)
    Sunil R Hingorani; Fiscal Year: 2010
    ..In addition, the contractor will incorporate known and postulated risk factors for pancreas cancer in models designed to improve the performance of a plasma marker(s) to detect disease early. ..
  30. LYMPHOMA: DIAGNOSIS BY BLOOD AND LIVER TESTS
    ANNEMARIE HERZFELD; Fiscal Year: 1980
    ....
  31. THE ROLE OF TOBACCO-SPECIFIC NITROSAMINES IN PANCREATIC CANCER
    Bogdan Prokopczyk; Fiscal Year: 2007
    ..The result of this study will further support the role of cigarette smoking and underscore the likelihood of dietary fat as a modulator of the development of human pancreatic cancer that is suggested by epidemiological observations. ..
  32. Targeting Akt/NF-kappa beta for Pancreatic Cancer Therapy
    Fazlul Sarkar; Fiscal Year: 2007
    ..These results will provide mechanistic as well as pre-clinical data in support of our hypotheses and may open new and novel avenues for the treatment of human pancreatic cancer. ..
  33. INTRAPERITONEAL GEMCITABINE--PHASE I & PARMACOKINETICS
    Elizabeth Poplin; Fiscal Year: 1999
    ..Moreover, the proposed pharmacodynamic studies will provide important new data with regard to possible mechanisms of resistance to gemcitabine that are operative in patients. ..
  34. A Sequencing Microarray for Mitochondrial Mutations
    Anirban Maitra; Fiscal Year: 2004
    ..This study will serve as a model for array-based diagnosis of cancer in clinical samples. ..
  35. Evaluation of Src Inhibition in Pancreas Cancer
    Wells Messersmith; Fiscal Year: 2009
    ..AZD0530 is a novel oral inhibitor of Src, which was of the first cancer-causing genes discovered several decades ago, and it is hoped the results will help guide us to better use of such drugs in the clinic. ..
  36. Pancreas Cancer Specialized Program of Research Excelle*
    Anton Wellstein; Fiscal Year: 2007
    ..This SPORE is also establishing interactions with SPOREs in other institutions as well as with other NCI- and NIH-funded programs to promote the aggressive development of novel therapies for the control of pancreas cancer ..
  37. Randomized Trial of EUS Neurolysis in Pancreas Cancer
    Michael Wallace; Fiscal Year: 2006
    ..The primary outcome will be a reduction in pain at 1 month. Secondary outcomes will include the durability of pain control, quality of life, narcotic use and narcotic side effects. [unreadable] [unreadable]..
  38. n-3 Fatty Acid & Host Responses to Oral Infection
    KESAVALU LAKSHMYYA; Fiscal Year: 2003
    ..disorders, cardiovascular diseases, increasing anti tumorigenic effects on breast cancer, colon cancer, pancreatic neoplasms, and improving bacterial and autoimmune responses...
  39. MOLECULAR CYTOLOGY IN HUMAN PANCRETIC CANCER
    JAMES JAMIESON; Fiscal Year: 1990
    ..This analytical scheme should enable us to test the hypothesis that human pancreatic neoplasms reflect aberrant stages in the normal differentiation process and should allow us to identify potential ..
  40. Depression, Cytokines, and Pancreatic Cancer
    William Breitbart; Fiscal Year: 2006
    ..abstract_text> ..
  41. Target Stat3 in pancreatic cancer using novel small molecule inhibitors
    JIAYUH contact LIN; Fiscal Year: 2010
    ..Our long-term goal is to target Stat3 as a new therapeutic approach for pancreatic cancer using novel small molecule inhibitors with the ultimate goal of improving the overall survival rate for human pancreatic cancer. ..
  42. TRANSGENIC ANM MODEL/PANCREATIC DUCT CELL ADENOCARCINOMA
    Marsha Frazier; Fiscal Year: 1991
    ..The development of an adequate animal model is even more important when one considers these limitations...
  43. THE PanINs OF PANCREATITIS,PANCREAS CANCER AND CONTROLS
    Michael Goggins; Fiscal Year: 2002
    ..abstract_text> ..
  44. Pancreas cancer analysis-SF Bay Area case-control study
    ELIZABETH HOLLY; Fiscal Year: 2005
    ..Data on modifiable risk factors may provide new and provocative results of 3ublic health importance for this devastating disease. ..
  45. Development of Immunodiagnostics for Pancreatic Cancer
    Hossein Ghanbari; Fiscal Year: 2002
    ....
  46. EPIDEMIOLOGIC RESEARCH IN CANCER ETIOLOGY
    Thomas Mack; Fiscal Year: 1992
    ....
  47. GENETIC EPIDEMIOLOGY OF PANCREAS CANCER
    Ralph Hruban; Fiscal Year: 2000
    ..This project thus anticipates the new analytic challenges of Internet-based subject accrual, as well as providing a basis for a large-multicenter study to understand the genetic etiology of pancreas cancer. ..
  48. Pilot Study of Pancreas Cancer & Diabetes Genes in CARET
    Melissa Austin; Fiscal Year: 2006
    ..The results may facilitate translational studies of early detection and prevention of pancreatic cancer, especially among patients diagnosed with diabetes. [unreadable] [unreadable]..
  49. Mechanisms of Tumorigenesis in Pancreatic Epithelial Cells
    Paul Chiao; Fiscal Year: 2009
    ..abstract_text> ..
  50. CASE CONTROL STUDY OF CARCINOMA OF THE PANCREAS
    Thomas Mack; Fiscal Year: 1980
    ..It will be administered to both cases and neighborhood controls as soon as possible after the cases have been diagnosed. Standard matched pair analyses of multiple variables will be performed on the data from the questionnaire...
  51. GASTROINTESTINAL PROGRAM PROJECT
    John Potter; Fiscal Year: 2002
    ....
  52. miRNA Expression Profiling
    David Brown; Fiscal Year: 2007
    ..unreadable] [unreadable] [unreadable]..
  53. The role of EGFR signaling in progression of Kras-induced pacreatic tumors
    Anna Means; Fiscal Year: 2007
    ..The studies proposed here investigate EGFR signaling as a potential biomarker and/or therapeutic target, by studying its effects on tumorigenesis in a mouse model of pancreatic cancer. [unreadable] [unreadable] [unreadable]..
  54. PKC Beta Inhibition With Gemcitabine And Radiation In Pancreas Cancer
    Edgar Ben Josef; Fiscal Year: 2008
    ..Based on its scientific merit and our institutional track record in translational research in pancreas cancer, we feel it is highly likely that this research will prove beneficial. [unreadable] [unreadable] [unreadable]..